Cargando…

Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kameda, Takuro, Shide, Kotaro, Yamaji, Takumi, Kamiunten, Ayako, Sekine, Masaaki, Hidaka, Tomonori, Kubuki, Yoko, Sashida, Goro, Aoyama, Kazumasa, Yoshimitsu, Makoto, Abe, Hiroo, Miike, Tadashi, Iwakiri, Hisayoshi, Tahara, Yoshihiro, Yamamoto, Shojiro, Hasuike, Satoru, Nagata, Kenji, Iwama, Atsushi, Kitanaka, Akira, Shimoda, Kazuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535894/
https://www.ncbi.nlm.nih.gov/pubmed/26484191
http://dx.doi.org/10.1016/j.gdata.2015.04.002
_version_ 1782385667930587136
author Kameda, Takuro
Shide, Kotaro
Yamaji, Takumi
Kamiunten, Ayako
Sekine, Masaaki
Hidaka, Tomonori
Kubuki, Yoko
Sashida, Goro
Aoyama, Kazumasa
Yoshimitsu, Makoto
Abe, Hiroo
Miike, Tadashi
Iwakiri, Hisayoshi
Tahara, Yoshihiro
Yamamoto, Shojiro
Hasuike, Satoru
Nagata, Kenji
Iwama, Atsushi
Kitanaka, Akira
Shimoda, Kazuya
author_facet Kameda, Takuro
Shide, Kotaro
Yamaji, Takumi
Kamiunten, Ayako
Sekine, Masaaki
Hidaka, Tomonori
Kubuki, Yoko
Sashida, Goro
Aoyama, Kazumasa
Yoshimitsu, Makoto
Abe, Hiroo
Miike, Tadashi
Iwakiri, Hisayoshi
Tahara, Yoshihiro
Yamamoto, Shojiro
Hasuike, Satoru
Nagata, Kenji
Iwama, Atsushi
Kitanaka, Akira
Shimoda, Kazuya
author_sort Kameda, Takuro
collection PubMed
description Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more than 90% of cases [1], [2]. Mutations in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated cells therefore they are considered as “driver” gene mutations. In addition to the above driver gene mutations mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%–30% of cases respectively [3]. Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth of differentiated cells and only exhibit subtle clinical phenotypes [[4], [6], [7], [8],5]. It was unclear how mutations in such epigenetic regulators influenced abnormal HSCs with driver gene mutations how they influenced the disease phenotype or whether a single driver gene mutation was sufficient for the initiation of human MPNs. Therefore we focused on JAK2V617F and loss of TET2—the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators—and examined the influence of single or double mutations on HSCs (Lineage(−)Sca-1(+)c-Kit(+) cells (LSKs)) by functional analyses and microarray whole-genome expression analyses [9]. Gene expression profiling showed that the HSC fingerprint genes [10] was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F–LSKs compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F–LSKs in terms of their HSC fingerprint genes but the expression of individual genes differed between the two groups. Among 245 HSC fingerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F–LSKs. These altered gene expressions might partly explain the mechanisms of initiation and progression of MPNs which was observed in the functional analyses [9]. Here we describe gene expression profiles deposited at the Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and quality control analyses.
format Online
Article
Text
id pubmed-4535894
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-45358942015-10-19 Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms Kameda, Takuro Shide, Kotaro Yamaji, Takumi Kamiunten, Ayako Sekine, Masaaki Hidaka, Tomonori Kubuki, Yoko Sashida, Goro Aoyama, Kazumasa Yoshimitsu, Makoto Abe, Hiroo Miike, Tadashi Iwakiri, Hisayoshi Tahara, Yoshihiro Yamamoto, Shojiro Hasuike, Satoru Nagata, Kenji Iwama, Atsushi Kitanaka, Akira Shimoda, Kazuya Genom Data Data in Brief Article Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and the gradual expansion of malignant intramedullary/extramedullary hematopoiesis. In MPNs mutations in JAK2 MPL or CALR are detected mutually exclusive in more than 90% of cases [1], [2]. Mutations in them lead to the abnormal activation of JAK/STAT signaling and the autonomous growth of differentiated cells therefore they are considered as “driver” gene mutations. In addition to the above driver gene mutations mutations in epigenetic regulators such as TET2 DNMT3A ASXL1 EZH2 or IDH1/2 are detected in about 5%–30% of cases respectively [3]. Mutations in TET2 DNMT3A EZH2 or IDH1/2 commonly confer the increased self-renewal capacity on normal hematopoietic stem cells (HSCs) but they do not lead to the autonomous growth of differentiated cells and only exhibit subtle clinical phenotypes [[4], [6], [7], [8],5]. It was unclear how mutations in such epigenetic regulators influenced abnormal HSCs with driver gene mutations how they influenced the disease phenotype or whether a single driver gene mutation was sufficient for the initiation of human MPNs. Therefore we focused on JAK2V617F and loss of TET2—the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators—and examined the influence of single or double mutations on HSCs (Lineage(−)Sca-1(+)c-Kit(+) cells (LSKs)) by functional analyses and microarray whole-genome expression analyses [9]. Gene expression profiling showed that the HSC fingerprint genes [10] was statistically equally enriched in TET2-knockdown-LSKs but negatively enriched in JAK2V617F–LSKs compared to that in wild-type-LSKs. Double-mutant-LSKs showed the same tendency as JAK2V617F–LSKs in terms of their HSC fingerprint genes but the expression of individual genes differed between the two groups. Among 245 HSC fingerprint genes 100 were more highly expressed in double-mutant-LSKs than in JAK2V617F–LSKs. These altered gene expressions might partly explain the mechanisms of initiation and progression of MPNs which was observed in the functional analyses [9]. Here we describe gene expression profiles deposited at the Gene Expression Omnibus (GEO) under the accession number GSE62302 including experimental methods and quality control analyses. Elsevier 2015-04-09 /pmc/articles/PMC4535894/ /pubmed/26484191 http://dx.doi.org/10.1016/j.gdata.2015.04.002 Text en © 2015 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Data in Brief Article
Kameda, Takuro
Shide, Kotaro
Yamaji, Takumi
Kamiunten, Ayako
Sekine, Masaaki
Hidaka, Tomonori
Kubuki, Yoko
Sashida, Goro
Aoyama, Kazumasa
Yoshimitsu, Makoto
Abe, Hiroo
Miike, Tadashi
Iwakiri, Hisayoshi
Tahara, Yoshihiro
Yamamoto, Shojiro
Hasuike, Satoru
Nagata, Kenji
Iwama, Atsushi
Kitanaka, Akira
Shimoda, Kazuya
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title_full Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title_fullStr Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title_full_unstemmed Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title_short Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
title_sort gene expression profiling of loss of tet2 and/or jak2v617f mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
topic Data in Brief Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535894/
https://www.ncbi.nlm.nih.gov/pubmed/26484191
http://dx.doi.org/10.1016/j.gdata.2015.04.002
work_keys_str_mv AT kamedatakuro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT shidekotaro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT yamajitakumi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT kamiuntenayako geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT sekinemasaaki geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT hidakatomonori geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT kubukiyoko geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT sashidagoro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT aoyamakazumasa geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT yoshimitsumakoto geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT abehiroo geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT miiketadashi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT iwakirihisayoshi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT taharayoshihiro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT yamamotoshojiro geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT hasuikesatoru geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT nagatakenji geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT iwamaatsushi geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT kitanakaakira geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms
AT shimodakazuya geneexpressionprofilingoflossoftet2andorjak2v617fmutanthematopoieticstemcellsfrommousemodelsofmyeloproliferativeneoplasms